"Real world" populations compared to clinical trials: can electronic record linkage be used to identify trial eligible patients?

Kelly Baillie, Christine Crearie, Tanja Mueller, Jiafeng Pan, Rob Jones, Marion Bennie, Jennifer Laskey

Research output: Contribution to journalMeeting abstract

Abstract

The Cancer Medicines Outcomes Programme aims to develop a process to determine clinical outcome data of cancer medicines in Scotland using routinely collected, electronically linked health records. Such, ‘real world’ patient populations are not necessarily directly comparable to clinical trial populations suggesting that outcome data from clinical trials may not provide a suitable benchmark. It is therefore important to be able to describe the demographics of a population to contextualise outcome data.

The aim of this study was to determine whether electronic record linkage (ERL) could be used to evaluate the potential eligibility of patients for inclusion in a relevant clinical trial.

Although many eligibility criteria used in the clinical trials could be applied to ERL, others could not. Nevertheless, ERL can be used to estimate the number of patients being treated with a specific cancer medicine who may have been eligible for inclusion in the respective trial – information that could be useful when comparing results from an observational study to clinical trial results.
LanguageEnglish
JournalJournal of Oncology Pharmacy Practice
Volume24
Issue number8 (Supplement)
Early online date25 Sep 2018
DOIs
Publication statusPublished - 1 Dec 2018
Event21st Annual BOPA Symposium - Birmingham, United Kingdom
Duration: 12 Oct 201814 Oct 2018

Fingerprint

Clinical Trials
Population
Benchmarking
Neoplasms
Scotland
Observational Studies
Medicine
Demography
Health

Cite this

@article{aeb49040475b496eaff8f8a21832b8cb,
title = "{"}Real world{"} populations compared to clinical trials: can electronic record linkage be used to identify trial eligible patients?",
abstract = "The Cancer Medicines Outcomes Programme aims to develop a process to determine clinical outcome data of cancer medicines in Scotland using routinely collected, electronically linked health records. Such, ‘real world’ patient populations are not necessarily directly comparable to clinical trial populations suggesting that outcome data from clinical trials may not provide a suitable benchmark. It is therefore important to be able to describe the demographics of a population to contextualise outcome data. The aim of this study was to determine whether electronic record linkage (ERL) could be used to evaluate the potential eligibility of patients for inclusion in a relevant clinical trial. Although many eligibility criteria used in the clinical trials could be applied to ERL, others could not. Nevertheless, ERL can be used to estimate the number of patients being treated with a specific cancer medicine who may have been eligible for inclusion in the respective trial – information that could be useful when comparing results from an observational study to clinical trial results.",
author = "Kelly Baillie and Christine Crearie and Tanja Mueller and Jiafeng Pan and Rob Jones and Marion Bennie and Jennifer Laskey",
year = "2018",
month = "12",
day = "1",
doi = "10.1177/1078155218796724",
language = "English",
volume = "24",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
number = "8 (Supplement)",

}

"Real world" populations compared to clinical trials : can electronic record linkage be used to identify trial eligible patients? / Baillie, Kelly; Crearie, Christine; Mueller, Tanja; Pan, Jiafeng; Jones, Rob; Bennie, Marion; Laskey, Jennifer.

In: Journal of Oncology Pharmacy Practice, Vol. 24, No. 8 (Supplement), 01.12.2018.

Research output: Contribution to journalMeeting abstract

TY - JOUR

T1 - "Real world" populations compared to clinical trials

T2 - Journal of Oncology Pharmacy Practice

AU - Baillie, Kelly

AU - Crearie, Christine

AU - Mueller, Tanja

AU - Pan, Jiafeng

AU - Jones, Rob

AU - Bennie, Marion

AU - Laskey, Jennifer

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The Cancer Medicines Outcomes Programme aims to develop a process to determine clinical outcome data of cancer medicines in Scotland using routinely collected, electronically linked health records. Such, ‘real world’ patient populations are not necessarily directly comparable to clinical trial populations suggesting that outcome data from clinical trials may not provide a suitable benchmark. It is therefore important to be able to describe the demographics of a population to contextualise outcome data. The aim of this study was to determine whether electronic record linkage (ERL) could be used to evaluate the potential eligibility of patients for inclusion in a relevant clinical trial. Although many eligibility criteria used in the clinical trials could be applied to ERL, others could not. Nevertheless, ERL can be used to estimate the number of patients being treated with a specific cancer medicine who may have been eligible for inclusion in the respective trial – information that could be useful when comparing results from an observational study to clinical trial results.

AB - The Cancer Medicines Outcomes Programme aims to develop a process to determine clinical outcome data of cancer medicines in Scotland using routinely collected, electronically linked health records. Such, ‘real world’ patient populations are not necessarily directly comparable to clinical trial populations suggesting that outcome data from clinical trials may not provide a suitable benchmark. It is therefore important to be able to describe the demographics of a population to contextualise outcome data. The aim of this study was to determine whether electronic record linkage (ERL) could be used to evaluate the potential eligibility of patients for inclusion in a relevant clinical trial. Although many eligibility criteria used in the clinical trials could be applied to ERL, others could not. Nevertheless, ERL can be used to estimate the number of patients being treated with a specific cancer medicine who may have been eligible for inclusion in the respective trial – information that could be useful when comparing results from an observational study to clinical trial results.

U2 - 10.1177/1078155218796724

DO - 10.1177/1078155218796724

M3 - Meeting abstract

VL - 24

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 8 (Supplement)

ER -